HOPO's chelator featured in Cancer Cytopathology

The development of HOPO Therapeutics’ lead drug candidate as a medical countermeasure for use in a radiological disaster scenario is detailed in an interview with co-founder Rebecca Abergel, Ph.D. in Cancer Cytopathology , a journal of the American Cancer Society . An effective treatment for removal of radioactive and other heavy metals from the body, its performance in preclinical trials has been vastly superior to any other chelating agent.

Learn more about our science